Prevalence of drug-resistant mutation among drug-treated HIV/AIDS inpatient in Airlangga University teaching hospital, Surabaya, Indonesia

1st International Conference on Tropical Medicine and Infectious Diseases (ICTROMI) Faculty of Medicine Universitas Sumatera Utara

Rachman, B.E.^1,2 ; Khairunisa, S.Q.^3 ; Witaningrum, A.M.^3 ; Yunifiar, M.Q.^3 ; Widiyanti, P.^3,4 ; Nasronudin^1,2

Airlangga University Hospital, Surabaya, Indonesia^1

Faculty of Medicine, Airlangga University, Surabaya, Indonesia^2

Institute of Tropical Disease, Airlangga University, Surabaya, Indonesia^3

Biomedical Engineering, Faculty of Science and Technology, Airlangga University, Surabaya, Indonesia^4

关键词: Antiretroviral treatment;    Antiretrovirals;    Drug resistance;    HIV/AIDS;    Indonesia;    Reverse transcriptases;    University teaching;   

Others  :  https://iopscience.iop.org/article/10.1088/1755-1315/125/1/012003/pdf
DOI  :  10.1088/1755-1315/125/1/012003

来源: IOP

【 摘 要 】

Increased use of antiretroviral therapy did not completely reduce the incidence of HIV/AIDShospitalization. Various factors can be involved. The aim of this study is to examine HIV-1 drug resistance mutations profile in drug-treated HIV/AIDS patients who underwent hospitalization. HIV/AIDS patients who are admitted to hospital who had received ART are included in the study and then examined for the presence of drug resistance-associated mutations. A total of 17 samples were included in the study, but only 11 samples that could be sequence analyzed. On the mutation examination of drug resistance in reverse transcriptase gene, it werefound a major mutation in K103N (9%) and G190A (9%). Most minor mutations were found in A98S (18.1%), followed by M41L, M184V, L210W, T215Y, V108l, Y181C and H221Y at 9% each. Whereas, on examination of drug resistance mutations in protease genes, there is a major mutation in I84V of 9%. Most minor mutations on M36I (45.4%), followed by L10I (36.3%), H69K (36.3%), I93L (27.2%), G16E, L89M, K20R 18.1%, L64V and V771I 9% respectively.A large number of mutated samples pose a challenge in long-term antiretroviral treatment, so a breakthrough policy is needed to minimize the impact.